The addition of tucatinib to a trastuzumab-capecitabine regimen improved progression-free survival (PFS) in patients with HER2+ metastatic breast cancer (MBC) previously treated with multiple HER2-targeted agents, according to the HER2CLIMB* study presented at SABCS** 2019. Additionally, this improved PFS was also noted in patients with brain metastases.
The use of acetaminophen 3 months prior to pregnancy was associated with an increased risk of adverse birth outcomes, such as low birth weight (LBW), preterm birth (PTB), and small-for-gestational-age (SGA), according to a recent study.
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Three anticonvulsant drugs — levetiracetam, fosphenytoin, and valproate — are equally effective in stopping life-threatening epilepsy seizures in patients who are unresponsive to benzodiazepines, thus providing affirmation for physicians that any of the three drugs can be used for treating status epilepticus, according to results from ESETT*.
Older patients and those with haemato-oncology conditions are less likely than surgical patients to be referred to infectious disease (ID) physicians within 48 hours of hospital admission. Furthermore, they appear to be more likely to require antibiotic stewardship programmes (ASP) due to inappropriate type or duration of antibiotic therapy despite ID consultations, a retrospective cross-sectional study from Singapore showed.
Asian ischaemic stroke patients with small and fragile cerebral vessels, as evidenced by the presence of multiple cerebral microbleeds (CMBs), may fare better with cilostazol than aspirin, as the former proves more effective at preventing cerebral haemorrhages especially when administered before white matter changes become extensive, according to the results of a subgroup analysis of the PICASSO* trial.
In-hospital initiation of the PCSK9* inhibitor evolocumab, on top of high-intensity statin therapy, in the very high-risk, acute phase of ACS** significantly reduced LDL-C levels — so much so that >95 percent of the patients achieved the recommended target levels — compared with high-intensity statin alone, the EVOPACS*** study has shown.
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.